Last $0.72 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

crown baus capital corp (CBCA) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $35.00
52 Week Low
01/6/15 - $0.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CROWN BAUS CAPITAL CORP (CBCA)

Related News

No related news articles were found.

crown baus capital corp (CBCA) Related Businessweek News

No Related Businessweek News Found

crown baus capital corp (CBCA) Details

Crown Baus Capital Corp., a development stage company, focuses on high-tech, pharmaceutical development, entertainment and media, education, and financial services industries. The company offers high-tech and marketing services, as well as a series of digital marketing events covering technical innovations and networking. It also focuses on pharmaceutical development, including horticulture, laboratories, manufacturing, distribution, patient education, and tracking. In addition, the company is focused on providing resources for motion pictures, Web movies, and television, which includes the documentary and reality television markets. Further, it provides educational resources and services to professionals. Additionally, Crown Baus Capital Corp. focuses on offering financial and banking solutions for various industries. The company was formerly known as Cannabis Capital Corp. and changed its name to Crown Baus Capital Corp. in June 2014. Crown Baus Capital Corp. was founded in 2011 and is headquartered in Beverly Hills, California.

crown baus capital corp (CBCA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

crown baus capital corp (CBCA) Key Developments

Crown Baus Capital Corp. Announces Executive Changes

The Board of Directors of Crown Baus Capital Corp. has appointed Raymond C. Dabney as Director, President and Chief Executive Officer. Mr. Dabney will replace Chad S. Johnson as President and Chief Executive Officer. Mr. Johnson was appointed as Chief Operating Officer and General Counsel of the Company and will remain as a Director of the Company. Mr. Dabney has been working as a managing consultant with the Company since March 2014. From October 2008 to November 5, 2014, Mr. Dabney was a managing consultant of Cannabis Science Inc. From November 5, 2014 to present, Mr. Dabney is a Director and President and Chief Executive Officer of Cannabis Science. Mr. Dabney will serve as the Company's Director and officer until his duly elected successor is appointed or he resigns.

Crown Baus Capital Corp. announced delayed 10-Q filing

On 09/16/2014, Crown Baus Capital Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Crown Baus Capital Corp. will Change its Ticker to CBCAE from CBCA

Effective August 18, 2014, Crown Baus Capital Corp. will change its OTC Bulletin Board stock ticker symbol to CBCAE from CBCA.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBCA:US $0.72 USD 0.00

CBCA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBCA.
View Industry Companies

Industry Analysis


Industry Average

Valuation CBCA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CROWN BAUS CAPITAL CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at